BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33225930)

  • 21. TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.
    Tu KH; Fan PY; Chen TD; Chuang WY; Wu CY; Ku CL; Tian YC; Yang CW; Fang JT; Yang HY
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.
    Masaki Y; Ueda Y; Yanagisawa H; Arita K; Sakai T; Yamada K; Mizuta S; Fukushima T; Takai K; Aoki S; Kawabata H
    Intern Med; 2023 Jan; 62(1):27-32. PubMed ID: 35598998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study.
    Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F
    Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
    Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
    Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TAFRO Syndrome.
    Igawa T; Sato Y
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide.
    Xia P; Zhang L; Zou M; Zhang T; Li R; Shi X; Wang J; Qin Y; Li X; Li J; Chen L
    Kidney Blood Press Res; 2020; 45(4):623-630. PubMed ID: 32492687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
    Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
    Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International definition of iMCD-TAFRO: future perspectives.
    Nishimura Y; Nishimura MF; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.
    Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M
    Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Case of Repeated TAFRO Syndrome-Like Symptoms and Retroperitoneal Hemorrhage in a Patient With Sjögren Syndrome.
    Ohta T; Oda N; Saito K; Tamiya S; Ueno T
    Cureus; 2020 Dec; 12(12):e12175. PubMed ID: 33489586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012).
    Kawabata H; Takai K; Kojima M; Nakamura N; Aoki S; Nakamura S; Kinoshita T; Masaki Y
    J Clin Exp Hematop; 2013; 53(1):57-61. PubMed ID: 23801135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological features of progressive renal involvement in TAFRO syndrome: A case report and literature review.
    Tanaka M; Tsujimoto H; Yamamoto K; Shimoda S; Oka K; Takeoka H
    Medicine (Baltimore); 2017 Oct; 96(40):e8216. PubMed ID: 28984775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome.
    Tsurumi H; Fujigaki Y; Yamamoto T; Iino R; Taniguchi K; Nagura M; Arai S; Tamura Y; Ota T; Shibata S; Kondo F; Kurose N; Masaki Y; Uchida S
    Intern Med; 2018 May; 57(10):1433-1438. PubMed ID: 29321413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TAFRO syndrome: A disease that known is half cured.
    Chen T; Feng C; Zhang X; Zhou J
    Hematol Oncol; 2023 Aug; 41(3):310-322. PubMed ID: 36148768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy.
    Hiramatsu S; Ohmura K; Tsuji H; Kawabata H; Kitano T; Sogabe A; Hashimoto M; Murakami K; Imura Y; Yukawa N; Yoshifuji H; Fujii T; Takaori-Kondo A; Mimori T
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(1):64-71. PubMed ID: 27181237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.
    Kubokawa I; Yachie A; Hayakawa A; Hirase S; Yamamoto N; Mori T; Yanai T; Takeshima Y; Kyo E; Kageyama G; Nagai H; Uehara K; Kojima M; Iijima K
    BMC Pediatr; 2014 Jun; 14():139. PubMed ID: 24890946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America.
    José FF; Kerbauy LN; Perini GF; Blumenschein DI; Pasqualin DDC; Malheiros DMAC; Campos Neto GC; de Souza Santos FP; Piovesan R; Hamerschlak N
    Medicine (Baltimore); 2017 Mar; 96(13):e6271. PubMed ID: 28353560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
    Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
    Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging.
    Nara M; Komatsuda A; Itoh F; Kaga H; Saitoh M; Togashi M; Kameoka Y; Wakui H; Takahashi N
    Intern Med; 2017; 56(10):1247-1252. PubMed ID: 28502946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report.
    Fujimoto S; Kawabata H; Kurose N; Kawanami-Iwao H; Sakai T; Kawanami T; Fujita Y; Fukushima T; Masaki Y
    Medicine (Baltimore); 2017 Dec; 96(50):e9220. PubMed ID: 29390349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.